Under this agreement, Bayer will license its haematological oncology products to Genzyme as part of the transfer of its current commercial portfolio.
Genzyme will then begin to market and sell Campath MabCampath (alemtuzumab), Fludara (fludarabine) and Leukine (sargramostim) globally.
Bayer HealthCare member of the executive committee Gunnar Riemann said that “this transaction provides greater long-term profitability for two of our most important franchises – MS and oncology”.
Genzyme will also be responsible for developing, marketing and selling the acquired oncology products.
Genzyme has contracted with Bayer to provide continuing services in certain countries over the transition period to ensure uninterrupted product supply to patients or support services to providers.